Evidence in context: One person's poison is another's acceptable risk

Evidence-Based Medicine

Volumn 14, Issue 1, 2009, Pages 5-

  Haynes, R Brian ^a   Hart, Lawrence ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; DRUG;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG SAFETY; HUMAN; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRESCRIPTION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SHORT SURVEY; ARTICLE; DRUG THERAPY; EVIDENCE BASED MEDICINE; RISK FACTOR;

DRUG THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK FACTORS;

EID: 59449104010     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebm.14.1.5     Document Type: Short Survey

References (9)

1. Moore RA, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord 2007;8:73.
2. Haynes RB, Devereaux PJ, Guyatt GH. Clinical expertise in the era of evidence-based medicine and patient choice [Editorial]. ACP J Club 2002;136:A11-4.
3. Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008;117:2104-13.
4. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44.
5. Solomon DH, Glynn RJ, Rothman KJ, et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 2008;59:1097-104.
6. Rostom A, Dubé C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007;146:376-89.
7. Spiegel BM, Farid M, Dulai GS, et al. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am J Med 2006;119:448.e27-36.
8. Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007;369:1621-6.
9. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum 2008;59:1058-73.